论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liang R, Liu Z, Piao X, Zuo M, Zhang J, Liu Z, Li Y, Lin Y
Received 24 July 2018
Accepted for publication 25 September 2018
Published 24 October 2018 Volume 2018:11 Pages 7417—7421
DOI https://doi.org/10.2147/OTT.S181239
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Leo Jen-Liang Su
Abstract: Malignant cancer is one of the most serious diseases that
currently endanger human health. As most tumors are diagnosed at an advanced
stage, the current treatments show poor therapeutic efficacy, and the patients
have poor prognosis. However, a 5-year survival rate higher than 80% could be
achieved if tumors are diagnosed at an early stage. Therefore, early diagnosis
and treatment play important roles in the prevention and treatment of malignant
tumors, and serum tumor markers are important for the early diagnosis of
malignant cancers. Recent studies have shown that GP73, a transmembrane protein,
has greater diagnostic value in primary liver cancer than in other types of
cancers, and research on the regulation of GP73 expression has unveiled broad
prospects in anticancer targeted therapy. Thus, GP73, as a new tumor marker,
deserves further study.
Keywords: GP73, malignant tumors, tumor marker, diagnosis, prognosis